Constitutional and acquired genetic variants in ARID5B in pediatric B-cell precursor acute lymphoblastic leukemia.


Journal

Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329

Informations de publication

Date de publication:
May 2024
Historique:
revised: 06 04 2024
received: 27 02 2024
accepted: 22 04 2024
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 13 5 2024
Statut: ppublish

Résumé

Constitutional polymorphisms in ARID5B are associated with an increased risk of developing high hyperdiploid (HeH; 51-67 chromosomes) pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL). Here, we investigated constitutional and somatic ARID5B variants in 1335 BCP ALL cases from five different cohorts, with a particular focus on HeH cases. In 353 HeH ALL that were heterozygous for risk alleles and trisomic for chromosome 10, where ARID5B is located, a significantly higher proportion of risk allele duplication was seen for the SNPs rs7090445 (p = 0.009), rs7089424 (p = 0.005), rs7073837 (p = 0.03), and rs10740055 (p = 0.04). Somatic ARID5B deletions were seen in 16/1335 cases (1.2%), being more common in HeH than in other genetic subtypes (2.2% vs. 0.4%; p = 0.002). The expression of ARID5B in HeH cases with genomic deletions was reduced, consistent with a functional role in leukemogenesis. Whole-genome sequencing and RNA-sequencing in HeH revealed additional somatic events involving ARID5B, resulting in a total frequency of 3.6% of HeH cases displaying a somatic ARID5B aberration. Overall, our results show that both constitutional and somatic events in ARID5B are involved in the leukemogenesis of pediatric BCP ALL, particularly in the HeH subtype.

Identifiants

pubmed: 38738968
doi: 10.1002/gcc.23242
doi:

Substances chimiques

ARID5B protein, human 0
Transcription Factors 0
DNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e23242

Subventions

Organisme : The Swedish Research Council
Organisme : Cancerfonden
Organisme : Barncancerfonden
Organisme : National Institute for Cancer Research funded by the European Union Next Generation EU
Organisme : Governmental Funding of Clinical Research within the National Health Service

Informations de copyright

© 2024 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC.

Références

Wang X, Nagl NG, Wilsker D, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J. 2004;383(Pt 2):319‐325.
Lin C, Song W, Bi X, et al. Recent advances in the ARID family: focusing on roles in human cancer. Onco Targets Ther. 2014;7:315‐324.
Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1001‐1005.
Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet. 2009;41(9):1006‐1010.
Paulsson K, Forestier E, Lilljebjörn H, et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010;107(50):21719‐21724.
Xu H, Yang W, Perez‐Andreu V, et al. Novel susceptibility variants at 10p12.31‐12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst. 2013;105(10):733‐742.
Studd JB, Vijayakrishnan J, Yang M, Migliorini G, Paulsson K, Houlston RS. Genetic and regulatory mechanism of susceptibility to high‐hyperdiploid acute lymphoblastic leukaemia at 10p21.2. Nat Commun. 2017;8:14616.
Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2012;30(7):751‐757.
Xu H, Zhao X, Bhojwani D, et al. ARID5B influences antimetabolite drug sensitivity and prognosis of acute lymphoblastic leukemia. Clin Cancer Res. 2020;26(1):256‐264.
Zhao X, Qian M, Goodings C, et al. Molecular mechanisms of ARID5B‐mediated genetic susceptibility to acute lymphoblastic leukemia. J Natl Cancer Inst. 2022;114(9):1287‐1295.
Chokkalingam AP, Hsu LI, Metayer C, et al. Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics. Cancer Causes Control. 2013;24(10):1789‐1795.
Chalise JP, Ehsani A, Lemecha M, et al. ARID5B regulates fatty acid metabolism and proliferation at the pre‐B cell stage during B cell development. Front Immunol. 2023;14:1170475.
Goodings C, Zhao X, McKinney‐Freeman S, Zhang H, Yang JJ. ARID5B influences B‐cell development and function in mouse. Haematologica. 2023;108(2):502‐512.
Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2009;48(8):637‐660.
Paulsson K, Lilljebjörn H, Biloglav A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47(6):672‐676.
Olsson L, Castor A, Behrendtz M, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population‐based series of pediatric B‐cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014;28(2):302‐310.
Woodward EL, Yang M, Moura‐Castro LH, et al. Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia. Nat Commun. 2023;14(1):1658.
McLeod C, Gout AM, Zhou X, et al. St. Jude cloud: a pediatric cancer genomic data‐sharing ecosystem. Cancer Discov. 2021;11(5):1082‐1099.
Newman S, Nakitandwe J, Kesserwan CA, et al. Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing. Cancer Discov. 2021;11(12):3008‐3027.
Rusch M, Nakitandwe J, Shurtleff S, et al. Clinical cancer genomic profiling by three‐platform sequencing of whole genome, whole exome and transcriptome. Nat Commun. 2018;9(1):3962.
Downing JR, Wilson RK, Zhang J, et al. The pediatric cancer genome project. Nat Genet. 2012;44(6):619‐622.
Duployez N, Abou Chahla W, Lejeune S, et al. Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia. Eur J Haematol. 2018;100(1):104‐107.
Zaliova M, Hovorkova L, Vaskova M, Hrusak O, Stary J, Zuna J. Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index < 1.16. Genes Chromosomes Cancer. 2016;55(9):727‐737.
Rasmussen M, Sundstrom M, Goransson Kultima H, et al. Allele‐specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 2011;12(10):R108.
McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res. 2010;20(9):1297‐1303.
Chen X, Schulz‐Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220‐1222.
Cameron DL, Baber J, Shale C, et al. GRIDSS2: comprehensive characterisation of somatic structural variation using single breakend variants and structural variant phasing. Genome Biol. 2021;22(1):202.
Lilljebjörn H, Henningsson R, Hyrenius‐Wittsten A, et al. Identification of ETV6‐RUNX1‐like and DUX4‐rearranged subtypes in paediatric B‐cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.

Auteurs

Charlotte Ragnarsson (C)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Paediatrics, Skåne University Hospital, Lund University, Lund, Sweden.

Minjun Yang (M)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Larissa Helena Moura-Castro (LH)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Efe Aydın (E)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Rebeqa Gunnarsson (R)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Linda Olsson-Arvidsson (L)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.

Henrik Lilljebjörn (H)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Thoas Fioretos (T)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.

Nicolas Duployez (N)

Laboratory of Haematology, Centre Hospitalier Universitaire (CHU) Lille, University of Lille, INSERM Unité 1277 Canther, Lille, France.

Marketa Zaliova (M)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic.
Childhood Leukaemia Investigation Prague (CLIP), Prague, Czech Republic.

Jan Zuna (J)

Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic.
Childhood Leukaemia Investigation Prague (CLIP), Prague, Czech Republic.

Anders Castor (A)

Department of Paediatrics, Skåne University Hospital, Lund University, Lund, Sweden.

Bertil Johansson (B)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.

Kajsa Paulsson (K)

Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH